New 'Smart Energy' Pouches Launch

Paraxanthine is the primary metabolite of caffeine in the human body, meaning it's what your liver converts caffeine into. Roughly 70-80% of caffeine is metabolized into paraxanthine, which is responsible for the majority of caffeine's stimulating and beneficial effects. The key marketing claim for enfinity® is providing the energy and focus of caffeine without the common negative side effects. This is because the ingredient bypasses other caffeine metabolites like theophylline and theobromine, which are often associated with jitters, anxiety, and sleep disruption. The ingredient is exclusively distributed by TSI Group, a global nutraceutical company. The pouch format is gaining significant traction as a delivery system for active ingredients. The global market for nicotine pouches is projected to grow from $5.4 billion in 2024 to over $25 billion by 2030, with the nicotine-free segment expected to see the fastest growth. This product also taps into the booming nootropics market, which was valued at over $5.45 billion in 2025 and is projected to continue its rapid expansion. This growth is driven by increasing consumer interest in cognitive health, mental performance, and overall well-being. IQ Pouch is entering a competitive space, with other companies like Doseology Sciences launching their own nicotine-free, caffeine-based energy pouches. The trend is toward functional pouches that often include a stack of ingredients like L-theanine, B-vitamins, and adaptogens alongside the primary stimulant. To appeal to its target market of athletes, enfinity® has secured an Informed Ingredient certification. This voluntary program tests for substances banned in sports, adding a layer of quality assurance for competitors concerned about compliance. The ingredient is also backed by 23 filed patents.